Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, Encompass Health Corporation (EHC) has a Wall Street consensus price target of $151.50, based on estimates from 26 covering analysts. With the stock currently trading at $107.88, this represents a potential upside of +40.4%. The company has a market capitalization of $10.79B.
Analyst price targets range from a low of $150.00 to a high of $153.00, representing a 2% spread in expectations. The median target of $151.50 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 21 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, EHC trades at a trailing P/E of 19.4x and forward P/E of 18.2x. The forward PEG ratio of 1.28 indicates reasonable valuation for growth. Analysts expect EPS to grow +12.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $125.11, with bear and bull scenarios of $72.87 and $255.10 respectively. Model confidence stands at 61/100, reflecting moderate uncertainty in projections.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how EHC stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for EHC is $151.5, representing 40.4% upside from the current price of $107.88. With 26 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
EHC has a consensus rating of "Buy" based on 26 Wall Street analysts. The rating breakdown is predominantly bullish, with 21 Buy/Strong Buy ratings. The consensus 12-month price target of $151.5 implies 40.4% upside from current levels.
With a forward P/E of 18.2199x, EHC trades at a relatively low valuation. The consensus target of $151.5 implies 40.4% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $153 for EHC, while the most conservative target is $150. The consensus of $151.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $255 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
EHC is heavily covered by Wall Street, with 26 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 20 have Buy ratings, 4 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month EHC stock forecast based on 26 Wall Street analysts shows a consensus price target of $151.5, with estimates ranging from $150 (bear case) to $153 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $125, with bear/bull scenarios of $73/$255.
Our quantitative valuation model calculates EHC's fair value at $125 (base case), with a bear case of $73 and bull case of $255. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 61/100.
EHC trades at a forward P/E ratio of 18.2x based on next-twelve-months earnings estimates compared to a trailing P/E of 19.4x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on EHC, with a "Buy" consensus rating and $151.5 price target (40.4% upside). 21 of 26 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
EHC analyst price targets range from $150 to $153, a 2% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $151.5 consensus represents the middle ground. Our model's $73-$255 range provides an independent fundamental perspective.